IVF Fundamental Analysis - INVO FERTILITY INC

Fundamental Rating

IVF gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. IVF may be in some trouble as it scores bad on both profitability and health. IVF is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

IVF had negative earnings in the past year.

In the past year IVF has reported a negative cash flow from operations.

In the past 5 years IVF always reported negative net income.

IVF had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of IVF (-155.09%) is worse than 88.71% of its industry peers.

IVF's Return On Equity of -499.38% is on the low side compared to the rest of the industry. IVF is outperformed by 82.80% of its industry peers.

		Industry Rank	Sector Rank
ROA	-155.09%
ROE	-499.38%
ROIC	N/A

ROA(3y)-109.72%

ROA(5y)-93.78%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IVF has a Gross Margin of 39.17%. This is in the lower half of the industry: IVF underperforms 68.28% of its industry peers.

In the last couple of years the Gross Margin of IVF has declined.

The Profit Margin and Operating Margin are not available for IVF so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	39.17%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-23.07%

GM growth 5Y-13.44%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IVF does not have a ROIC to compare to the WACC, probably because it is not profitable.

IVF has more shares outstanding than it did 1 year ago.

IVF has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, IVF has a worse debt to assets ratio.

2.2 Solvency

IVF has an Altman-Z score of -8.60. This is a bad value and indicates that IVF is not financially healthy and even has some risk of bankruptcy.

IVF's Altman-Z score of -8.60 is on the low side compared to the rest of the industry. IVF is outperformed by 75.27% of its industry peers.

IVF has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.

IVF has a Debt to Equity ratio (0.31) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.31
Debt/FCF	N/A
Altman-Z	-8.6

ROIC/WACCN/A

WACC5.41%

2.3 Liquidity

IVF has a Current Ratio of 0.12. This is a bad value and indicates that IVF is not financially healthy enough and could expect problems in meeting its short term obligations.

With a Current ratio value of 0.12, IVF is not doing good in the industry: 97.31% of the companies in the same industry are doing better.

A Quick Ratio of 0.10 indicates that IVF may have some problems paying its short term obligations.

IVF has a Quick ratio of 0.10. This is amonst the worse of the industry: IVF underperforms 97.31% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.12
Quick Ratio	0.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IVF shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -808.80%.

IVF shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.50%.

Measured over the past years, IVF shows a very strong growth in Revenue. The Revenue has been growing by 34.57% on average per year.

EPS 1Y (TTM)-808.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.06%

Revenue 1Y (TTM)11.5%

Revenue growth 3Y16.23%

Revenue growth 5Y34.57%

Sales Q2Q%22.8%

3.2 Future

The Earnings Per Share is expected to grow by 14.71% on average over the next years. This is quite good.

The Revenue is expected to grow by 10.00% on average over the next years. This is quite good.

EPS Next Y92.84%

EPS Next 2Y39.17%

EPS Next 3Y23.45%

EPS Next 5Y14.71%

Revenue Next Year10.02%

Revenue Next 2Y10.01%

Revenue Next 3Y10%

Revenue Next 5Y10%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVF. In the last year negative earnings were reported.

Also next year IVF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IVF's earnings are expected to grow with 23.45% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y39.17%

EPS Next 3Y23.45%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IVF!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

INVO FERTILITY INC

NASDAQ:IVF (12/30/2025, 8:00:03 PM)

Premarket: 0.814 0 (-0.12%)

0.815

+0.07 (+9.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-17 2025-11-17/bmo

Earnings (Next)04-28 2026-04-28/amc

Inst Owners0.96%

Inst Owner Change4510.52%

Ins Owners0.06%

Ins Owner Change-0.69%

Market Cap1.54M

Revenue(TTM)6.94M

Net Income(TTM)-29.21M

Analysts80

Price Target146.88 (17922.09%)

Short Float %N/A

Short Ratio0.05

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)3.08%

Min Revenue beat(2)-3.98%

Max Revenue beat(2)10.15%

Revenue beat(4)3

Avg Revenue beat(4)60.92%

Min Revenue beat(4)-3.98%

Max Revenue beat(4)236.57%

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)700%

PT rev (3m)700%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)-700%

EPS NY rev (3m)-700%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.22
P/FCF	N/A
P/OCF	N/A
P/B	0.26
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-644.61

EYN/A

EPS(NY)-23.76

Fwd EYN/A

FCF(TTM)-4.11

FCFYN/A

OCF(TTM)-4.05

OCFYN/A

SpS3.67

BVpS3.09

TBVpS-0.77

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-155.09%
ROE	-499.38%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	39.17%
FCFM	N/A

ROA(3y)-109.72%

ROA(5y)-93.78%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-23.07%

GM growth 5Y-13.44%

F-Score3

Asset Turnover0.37

Health

		Industry Rank	Sector Rank
Debt/Equity	0.31
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	14.3%
Cap/Sales	1.59%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.12
Quick Ratio	0.1
Altman-Z	-8.6

F-Score3

WACC5.41%

ROIC/WACCN/A

Cap/Depr(3y)84.61%

Cap/Depr(5y)530.77%

Cap/Sales(3y)6.25%

Cap/Sales(5y)7.65%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-808.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.06%

EPS Next Y92.84%

EPS Next 2Y39.17%

EPS Next 3Y23.45%

EPS Next 5Y14.71%

Revenue 1Y (TTM)11.5%

Revenue growth 3Y16.23%

Revenue growth 5Y34.57%

Sales Q2Q%22.8%

Revenue Next Year10.02%

Revenue Next 2Y10.01%

Revenue Next 3Y10%

Revenue Next 5Y10%

EBIT growth 1Y-61.79%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-43.58%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-51.93%

OCF growth 3YN/A

OCF growth 5YN/A

INVO FERTILITY INC / IVF FAQ

What is the ChartMill fundamental rating of INVO FERTILITY INC (IVF) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IVF.

Can you provide the valuation status for INVO FERTILITY INC?

ChartMill assigns a valuation rating of 1 / 10 to INVO FERTILITY INC (IVF). This can be considered as Overvalued.

How profitable is INVO FERTILITY INC (IVF) stock?

INVO FERTILITY INC (IVF) has a profitability rating of 0 / 10.

What is the financial health of INVO FERTILITY INC (IVF) stock?

The financial health rating of INVO FERTILITY INC (IVF) is 1 / 10.

INVO FERTILITY INC (IVF) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

INVO FERTILITY INC / IVF FAQ

What is the ChartMill fundamental rating of INVO FERTILITY INC (IVF) stock?

Can you provide the valuation status for INVO FERTILITY INC?

How profitable is INVO FERTILITY INC (IVF) stock?

What is the financial health of INVO FERTILITY INC (IVF) stock?